CA-GREEN-STREET
30.1.2024 09:08:27 CET | Business Wire | Press release
Green Street, the preeminent provider of actionable commercial real estate intelligence and analytics, has released its 2024 Pan-European Sector Outlooks, a bundle of in-depth research reports covering commercial real estate. The Outlook reports provide a 360-degree view of the four core property sectors and can be utilized in conjunction with our Market Forecasts tool, which provides five-year forecasts for operating fundamentals and valuation metrics across various scenarios for the top 30 Pan-European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130899540/en/
New Insights! Green Street's 2024 Sector Outlooks and Expanded Market Reports Are Here. Explore Sector Dynamics, Market Fundamentals and Valuation Trends. (Graphic: Business Wire)
The 2024 Pan-European Industrial, Office, Residential and Retail Sector Outlooks include supply/demand analysis, growth forecasts, valuation metrics, and NUTS3 and Market Grades representing long-term growth potential.
“Industrial and retail remain Green Street’s preferred sectors from a long-term hold perspective. Strength of the demand has been fueling industrial rental growth, whilst high incoming yield in retail bolster returns,” explains Marie Dormeuil, Head of European Market Analytics. “On the other hand, office remains a laggard for the fourth consecutive year. The observed yield expansion is not enough to offset the drag in fundamentals entailed by the bifurcation in tenants’ demand in favour of prime offices.”
Below are key takeaways from each sector:
- Industrial: Opportunities Plentiful
M-RevPAM growth – a Green Street proprietary metric that combines effective market rent and occupancy – is forecast to exhibit a more level-playing field than history has played out, and whilst there is a wide dispersion between key European cities, growth is positive across the board. There are signals that values have bottomed and yields are showing tentative signs of tightening. Institutional investors who have been hopeful for a lower price point and/or sought greater assurance on the operating backdrop now have their potential opportunity.
- Retail: Firmer Footings
Europe's downbeat consumer has kept spending despite the uncertain outlook. The pressure on consumer discretionary spend which has been well documented in news headlines has not (yet) necessarily translated into weakening tenant sales. Retailer occupational fundamentals are surprisingly sturdy and, moreover, given the value destruction experienced in the pandemic, several green shoots are emerging in terms of rental growth. Combined with the high initial yields on offer, potential unlevered returns are alluring for centres that are dominant in their catchment. According to Green Street’s Multichannel Desirability Index, which ranks markets in order of where a retailer (and landlord) is most likely to flourish, U.K. cities screen amongst the most favourable places for both ecommerce and physical retailers.
- Office: Crystal Ball Gazing
Key risks to the office sector include a softer macro-outlook (redundancies) and improved productivity due to remote working. The bifurcation in favour of 'A' space that began to assert itself post-pandemic accelerated in '23, eroding further fundamentals for 'B'-quality. Flight to quality by tenants should accelerate operational obsolescence of some of Europe’s more secondary office stock, leading to demolition or conversion to other uses. Developers are likely to find better risk-adjusted (i.e., lower environmental impact, lower development risk) returns on offer by pursuing major refurbishment and/or redevelopment works relative to ground-up new construction projects.
- Residential: More Cheery Than Gloomy
The positive long-term structural trends of solid demand (household formation and immigration) and lack of supply outweigh the headwinds facing the European residential sector. Meanwhile, the outlook for new residential construction is muted as the rise in interest rates has derailed development economics. Pan-European residential asset prices are down ~24% from mid-'22 peak and a bottom might be forming; signals from the fixed income and public equity markets are pointing to moderate upside to private market valuations for the first time after 18 months. Governments' appetite for rent controls and stretched affordability are near-term risks to watch out for.
Request a sample report for more information on Green Street’s Sector Outlooks.
Register now to join the upcoming Pan-European Private Markets Webinar.
To learn more about Green Street’s Market Forecasts Tool, click here.
About Green Street
Green Street is the preeminent provider of actionable commercial real estate research, news, data, analytics, and advisory services in the U.S. and Europe. For more than 35 years, Green Street has delivered unparalleled intelligence and trusted data on the public and private real estate markets, helping investors, banks, lenders, and other industry participants optimize investment and strategic decisions. The firm delivers exclusive market information, conclusion-driven insights, and predictive analytics through a SaaS platform.
Green Street's US Research, Data, and Analytics products along with its global news publications are not provided as an investment advisor nor in the capacity of a fiduciary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130899540/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
